Pci Medicine India Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 19-12-2024
- Paid Up Capital ₹ 0.48 M
as on 19-12-2024
- Company Age 13 Year, 8 Months
- Last Filing with ROC 31 Mar 2015
- Open Charges ₹ 7.22 M
as on 19-12-2024
- Revenue 18.85%
(FY 2015)
- Profit -83.57%
(FY 2015)
- Ebitda 132.24%
(FY 2015)
- Net Worth 3.20%
(FY 2015)
- Total Assets 7.23%
(FY 2015)
About Pci Medicine India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2015. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.48 M.
The company currently has active open charges totaling ₹7.22 M.
Rekha Singal and Pardeep Singhal serve as directors at the Company.
- CIN/LLPIN
U24232HR2011PTC042911
- Company No.
042911
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 May 2011
- Date of AGM
30 Sep 2015
- Date of Balance Sheet
31 Mar 2015
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Hisar, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Pci Medicine India Private Limited offer?
Pci Medicine India Private Limited offers a wide range of products and services, including Pantoprazole Drugs, Pantoprazole Sodium Injection, Anti Infective Drugs & Medicines, Antifungal Cream, Ointment & Powder, Anti Inflammatory Drugs, Deflazacort Tablets, Antacid Drugs, Rabeprazole Domperidone Capsule, Methylprednisolone Tablet, Luliconazole Cream.
Who are the key members and board of directors at Pci Medicine India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rekha Singal  | Director | 02-Aug-2017 | Current |
| Pardeep Singhal | Director | 16-Nov-2011 | Current |
Financial Performance of Pci Medicine India.
Pci Medicine India Private Limited, for the financial year ended 2015, experienced significant growth in revenue, with a 18.85% increase. The company also saw a substantial fall in profitability, with a 83.57% decrease in profit. The company's net worth moved up by a moderate rise of 3.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pci Medicine India?
In 2015, Pci Medicine India had a promoter holding of 66.67% and a public holding of 33.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 02 May 2014 | ₹7.22 M | Open |
How Many Employees Work at Pci Medicine India?
Unlock and access historical data on people associated with Pci Medicine India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pci Medicine India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pci Medicine India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
